13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Utility of Intraventricular Pressure Gradient for Early Detection of Chemotherapy-Induced Subclinical Cardiac Dysfunction in Dogs

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Simple Summary

          Cardiotoxicity is a serious side effect of doxorubicin in cancer patients due to the risk of development of heart failure. Early detection of doxorubicin-induced cardiomyopa-thy (DXR-ICM) has become a major objective to reduce heart failure in cancer patients. Echocar-diography is the gold standard method to diagnose cardiac diseases when cardiac dysfunction is prominent; however, it still cannot predict or early diagnose heart failure before functional de-cline. The intraventricular blood flow is characterized by intraventricular pressure gradients (IVPG) that created due to the suction of blood by the ventricles. Currently, advanced imaging techniques allow non-invasive assessment of IVPG from color M-mode echocardiography (CMME) after image processing for the clinical setting. Studies revealed that IVPG indices are promising for the early diagnosis of cardiac dysfunction. In this study, we aimed to investigate the usefulness of IVPG to detect cardiac function changes after DXR administration in dogs.

          Abstract

          Early detection of doxorubicin (DXR)-induced cardiomyopathy (DXR-ICM) is crucial to improve cancer patient outcomes and survival. In recent years, the intraventricular pressure gradient (IVPG) has been a breakthrough as a sensitive index to assess cardiac function. This study aimed to evaluate the usefulness of IVPG for the early detection of chemotherapy-related cardiac dysfunction. For this purpose, six dogs underwent conventional, speckle tracking, and color M-mode echocardiography concomitantly with pressure-and-volume analysis by conductance catheter. The cardiac function measurements were assessed before DXR administration (baseline, Pre), at the end of treatment protocol (Post), and at 1.5 years follow-up (Post2). The result showed a significant reduction in the left ventricular end-systolic pressure-volume (Emax: 4.4 ± 0.7, 6.1 ± 1.6 vs. 8.4 ± 0.8 mmHg/mL), total-IVPG (0.59 ± 0.12, 0.62 ± 0.15 vs. 0.86 ± 0.12 mmHg), and mid-IVPG (0.28 ± 0.12, 0.31 ± 0.11 vs. 0.48 ± 0.08 mmHg), respectively in Post2 and Post compared with the baseline ( p < 0.05). Mid-to-apical IVPG was also reduced in Post2 compared with the baseline (0.29 ± 0.13 vs. 0.51 ± 0.11). Meanwhile, the fraction shortening, ejection fraction, and longitudinal strain revealed no change between groups. Total and mid-IVPG were significantly correlated with Emax (R = 0.49; p < 0.05, both) but only mid-IVPG was a predictor for Emax (R 2 = 0.238, p = 0.040). In conclusion, this study revealed that impairment of contractility was the initial changes observed with DXR-ICM in dogs and only IVPG could noninvasively detect subclinical alterations in cardiac function. Color M-mode echocardiography-derived IVPG could be a potential marker for the early detection of doxorubicin cardiomyopathy.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: not found
          • Article: not found

          Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

            Previous studies of the prognosis of patients with heart failure due to cardiomyopathy categorized patients according to whether they had ischemic or nonischemic disease. The prognostic value of identifying more specific underlying causes of cardiomyopathy is unknown. We evaluated the outcomes of 1230 patients with cardiomyopathy. The patients were grouped into the following categories according to underlying cause: idiopathic cardiomyopathy (616 patients), peripartum cardiomyopathy (51); and cardiomyopathy due to myocarditis (111), ischemic heart disease (91), infiltrative myocardial disease (59), hypertension (49), human immunodeficiency virus (HIV) infection (45), connective-tissue disease (39), substance abuse (37), therapy with doxorubicin (15), and other causes (117). Cox proportional-hazards analysis was used to assess the association between the underlying cause of cardiomyopathy and survival. During a mean follow-up of 4.4 years, 417 patients died and 57 underwent cardiac transplantation. As compared with the patients with idiopathic cardiomyopathy, the patients with peripartum cardiomyopathy had better survival (adjusted hazard ratio for death, 0.31; 95 percent confidence interval, 0.09 to 0.98), and survival was significantly worse among the patients with cardiomyopathy due to infiltrative myocardial disease (adjusted hazard ratio, 4.40; 95 percent confidence interval, 3.04 to 6.39), HIV infection (adjusted hazard ratio, 5.86; 95 percent confidence interval, 3.92 to 8.77), therapy with doxorubicin (adjusted hazard ratio, 3.46; 95 percent confidence interval, 1.67 to 7.18), and ischemic heart disease (adjusted hazard ratio, 1.52; 95 percent confidence interval, 1.07 to 2.17). The underlying cause of heart failure has prognostic value in patients with unexplained cardiomyopathy. Patients with peripartum cardiomyopathy appear to have a better prognosis than those with other forms of cardiomyopathy. Patients with cardiomyopathy due to infiltrative myocardial diseases, HIV infection, or doxorubicin therapy have an especially poor prognosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

              The purpose of this study was to evaluate the clinical relevance of anthracycline-induced cardiomyopathy (AC-CMP) and its response to heart failure (HF) therapy. The natural history of AC-CMP, as well as its response to modern HF therapy, remains poorly defined. Hence, evidence-based recommendations for management of this form of cardiomyopathy are still lacking. We included in the study 201 consecutive patients with a left ventricular ejection fraction (LVEF)
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Animals (Basel)
                Animals (Basel)
                animals
                Animals : an Open Access Journal from MDPI
                MDPI
                2076-2615
                14 April 2021
                April 2021
                : 11
                : 4
                : 1122
                Affiliations
                [1 ]VCA Japan Shiraishi Animal Hospital, Saitama 350-1304, Japan; k.matsuura.vet@ 123456gmail.com
                [2 ]Veterinary Surgery, Tokyo University of Agriculture and Technology, Tokyo 183-0054, Japan; kenkenvet@ 123456gmail.com (K.S.); sleeping_3straycat@ 123456yahoo.co.jp (K.S.); ruiyue1221@ 123456gmail.com (K.S.); seijirow.goya@ 123456gmail.com (S.G.); tomohiko7731-yoshida@ 123456yahoo.co.jp (T.Y.); pitipat_ki@ 123456rmutto.ac.th (P.K.); linahamabe@ 123456googlemail.com (L.H.)
                [3 ]Department of Animal Medicine (Internal Medicine), Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt
                [4 ]Department of Veterinary Surgery, Division of Veterinary Research, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido 080-8555, Japan; anco@ 123456vet.ne.jp
                [5 ]Department of Internal Medicine, Faculty of Veterinary Medicine, Uludag University, Bursa 16120, Turkey; zyilmaz@ 123456uludag.edu.tr
                [6 ]Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan; myifuku@ 123456juntendo.ac.jp (M.I.); takeshii@ 123456juntendo.ac.jp (T.I.); kentaka@ 123456juntendo.ac.jp (K.T.)
                Author notes
                [* ]Correspondence: dr_mandour@ 123456vet.suez.edu.eg or ahmedmandour287@ 123456gmail.com (A.S.M.); ryo@ 123456vet.ne.jp (R.T.); Tel./Fax: +81-42-367-5904 (R.T.)
                [†]

                Authors are contributed equally to this work.

                Author information
                https://orcid.org/0000-0002-6047-2865
                https://orcid.org/0000-0001-6256-4539
                https://orcid.org/0000-0002-2514-695X
                https://orcid.org/0000-0001-7995-4760
                https://orcid.org/0000-0003-2671-5074
                https://orcid.org/0000-0001-9948-6490
                Article
                animals-11-01122
                10.3390/ani11041122
                8070943
                33919889
                c34d6536-3fe3-49f6-91d6-2667162a268d
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 03 February 2021
                : 08 April 2021
                Categories
                Article

                cardiomyopathy,dogs,doxorubicin,echocardiography,heart failure,intraventricular pressure gradient,pressure-volume

                Comments

                Comment on this article